전체 8345
-
- Deputy Director for Management Seminar Series Featuring Harvey Coleman (NIH Only)
-
- - Harvey Coleman, author of "Empowering Yourself" (2011/12/17)
- - Category : DDM Seminar Series (NIH Only)
- On behalf of Colleen Barros, Deputy Director for Management (DDM), the NIH Training Center is pleased to announce the first seminar of the 2011 - 2012 DDM Seminar Series featuring Harvey Coleman. He will address the NIH community in a presentation about leveraging cultural differences and diversity in the business world in a presentation entitled ？？？Empowering Yourself？？？The Best Kept Secret in Organizational America.？？？
Harvey Coleman is the author of ？？？Empowering Yourself？？？The Organizational Game Revealed.？？？ He also recently produced a video-tape and workbook program entitled ？？？A World of Diversity, which seeks to capitalize on the opportunities inherent in a diverse workplace. Mr. Coleman is recognized both nationally and internationally as a public speaker, consultant and author and has been a regular speaker at Emory University？？？s executive MBA program and IBM？？？s International School in Belgium.
During his presentation, ？？？Empowering Yourself？？？The Best Kept Secret in Organizational America, Mr. Coleman will share his insights on how valuing different perspectives, cultures and life experiences will lead to better workplace decisions and a stronger team effort. Also to be discussed is the need to understand employee cultural experiences within the larger framework of organizational culture and value systems. This culture is defined by a set of ？？？Unwritten Rules？？？ that allow various cultures to communicate effectively, whether it is among individuals, departments, disciplines and even organizations and nations.
Knowledge of these unwritten expectations is the key to both individual and organizational success. In this session, the ？？？Rules of the Game？？？ will be clearly defined, allowing employees to make the choices necessary to take control of their careers. Knowing the rules is the leveling of the playing field for all cultures.
Click here to respond to a survey about this DDM Seminar
For additional information about the DDM Seminar Series and to view previous lectures, please visit:http://www.ddmseries.od.nih.gov
Deputy Director for Management Seminar Series Featuring Harvey Coleman (NIH Only)
-
- Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 3)
-
- - NCI, CDC, and OMAR (2011/12/16)
- - Category : Conferences
- Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. It is estimated that in 2010, approximately 32,000 American men died of prostate cancer and 218,000 were newly diagnosed with the disease. Most prostate cancers are detected by a blood test that measures prostate-specific antigen (PSA), a tumor marker. More than half of cancers detected with PSA screening are localized (confined to the prostate) and are not aggressive at diagnosis, and are unlikely to become life-threatening.
However, 90 percent of patients receive immediate treatment for prostate cancer, such as surgery or radiation therapy. In many patients, these treatments have substantial short- and long-term side effects without any clinical benefit. Appropriate management of screen-detected, early-stage, low-risk prostate cancer is an important public health issue given the number of men affected and the risk for adverse outcomes, such as diminished sexual function and loss of urinary control. Currently clinicians rely on two observational strategies as alternatives to immediate treatment of early-stage prostate cancer: watchful waiting and active surveillance.
To better understand the benefits and risks of active surveillance and other observational management strategies for PSA screening-detected, low-grade, localized prostate cancer, the National Institutes of Health has engaged in a rigorous assessment of the available scientific evidence. This process, sponsored by the National Cancer Institute, the Centers for Disease Control and Prevention, and the Office of Medical Applications of Research will culminate in a Consensus Development Conference December 5？？？7, 2011.
For more information, visit: http://consensus.nih.gov/
Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 3)
-
- Small Ripples, Big Waves: How Tiny Changes in the BCR Trigger B Cell Activation
-
- - Sue Pierce, Chief, Laboratory of Immunogenetics, NIAID (2011/12/16)
- - Category : Immunology
- Immunology Interest Group Seminar
Small Ripples, Big Waves: How Tiny Changes in the BCR Trigger B Cell Activation
-
- 4th Annual Trauma Spectrum Conference (Day 1)
-
- - NIH, DoD and the VA (2011/12/16)
- - Category : Conferences
- Bridging the Gap Between Research and Clinical Practice of Psychologicial Health and Traumatic Brain Injury: Prevention, Diagnosis, Treatment and Recovery for the Iraq and Afghanistan Cohort
The is a 2-day conference that will focus on advances in PTSD, traumatic brain injury, and related topics such as substance abuse, pain management, cognitive rehabilitation, neuro-imaging, women's health and comparative effectiveness research.
4th Annual Trauma Spectrum Conference (Day 1)
-
- Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 2)
-
- - NCI, CDC, and OMAR (2011/12/15)
- - Category : Conferences
- Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. It is estimated that in 2010, approximately 32,000 American men died of prostate cancer and 218,000 were newly diagnosed with the disease. Most prostate cancers are detected by a blood test that measures prostate-specific antigen (PSA), a tumor marker. More than half of cancers detected with PSA screening are localized (confined to the prostate) and are not aggressive at diagnosis, and are unlikely to become life-threatening.
However, 90 percent of patients receive immediate treatment for prostate cancer, such as surgery or radiation therapy. In many patients, these treatments have substantial short- and long-term side effects without any clinical benefit. Appropriate management of screen-detected, early-stage, low-risk prostate cancer is an important public health issue given the number of men affected and the risk for adverse outcomes, such as diminished sexual function and loss of urinary control. Currently clinicians rely on two observational strategies as alternatives to immediate treatment of early-stage prostate cancer: watchful waiting and active surveillance.
To better understand the benefits and risks of active surveillance and other observational management strategies for PSA screening-detected, low-grade, localized prostate cancer, the National Institutes of Health has engaged in a rigorous assessment of the available scientific evidence. This process, sponsored by the National Cancer Institute, the Centers for Disease Control and Prevention, and the Office of Medical Applications of Research will culminate in a Consensus Development Conference December 5？？？7, 2011.
For more information, visit: http://consensus.nih.gov/
Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 2)
-
- Words as Medicine
-
- - Laura Milstein (2011/12/15)
- - Category : Focus on You Wellness
- Focus on You Employee Wellness Lecture Series
Are words merely descriptive? Or can they also be prescriptive, affecting our bodies in ways that heal? Why do we hear ourselves saying the same things even though we want to say something new? How and where can we use words to create and expand what is possible for ourselves and for others?
Laura Milstein is a Personal Development Coach who works with clients to reduce stress and create energy through simple techniques, including use of language and movement. As a result, her clients are empowered to take action now to achieve their goals, including optimum work-life balance, self-care and the realization of long-held dreams. As a coach, her interests include how the mind (brain) works in the process of change, transformation and performance. She is a cognitive trainer with Learning Rx in Bethesda and a certified ski instructor who volunteers with Wounded Warriors during the winter.
Words as Medicine
-
- Mindfulness instruction for urban youth: what do we know?
-
- - Erica Maria Smit Sibinga, MD, MHS, Johns Hopkins School of Medicine (2011/12/15)
- - Category : NCCAM Lectures
- Erica Maria Smit Sibinga, M.D., M.H.S., is assistant professor, Division of General Pediatrics & Adolescent Medicine at the Johns Hopkins School of Medicine in Baltimore. She is also on the faculty of Johns Hopkins School of Medicine Center for Mind-Body Research, and is the clinical director of the Center for Addiction and Pregnancy at the Johns Hopkins Bayview Medical Center. Dr. Sibinga received her undergraduate degree from Wesleyan University in Middletown, CT and her medical degree from the University of Pennsylvania School of Medicine in Philadelphia. She completed her residency at Johns Hopkins Hospital and her fellowship at Johns Hopkins University School of Medicine, later obtaining a masters of health science at the Johns Hopkins Bloomberg School of Public Health. Her ongoing research includes: reducing stress in HIV infected youth through mindfulness training; mindfulness based stress reduction: a nonpharmacological approach to support children and youth with depression and/or anxiety; preventing depression in disconnected African-American adolescents and young adults; and meditation programs for stress and well-being.
The Complementary and Integrative Medicine Consult Service Lecture Series Sponsored by NCCAM Provides NIH Clinical Center Staff with Opportunities to Learn more about How the Integration of Various Complementary and Alternative Medicine Treatments Can Affect Approaches in the Research and Practice for Medicine
Mindfulness instruction for urban youth: what do we know?
-
- Annual Meeting of the Medical Staff (NIH Only)
-
- - Sponsored by the Medical Executive Committee (2011/12/15)
- - Category : NIH Only
- 2011 Annual Meeting of the CC Medical Staff
Annual Meeting of the Medical Staff (NIH Only)
-
- ORS Directors Brown Bag Lunch Series - December 2011 (NIH Only)
-
- - ORS (2011/12/15)
- - Category : NIH Only
- This optional lunch series is designed to bring together ORS FTE employees in an informal setting to receive the latest information, ask questions, provide feedback and generally discuss and interact on topics of the day.
For more information, visit: http://orsweb.od.nih.gov/sites/od/default.aspx
ORS Directors Brown Bag Lunch Series - December 2011 (NIH Only)
-
- STEP Comparative Effectiveness Research: Choppy Waters or Smooth Sailing? (HHS Only)
-
- - Suzanne Goldberg (2011/12/14)
- - Category : STEP (HHS Only)
- The NIH search for what works best to improve patients' outcomes has evolved from best care strategy trials to Comparative Effectiveness Research (CER). Conducting a CER trial is challenging due to the diversity of stakeholders, their complex relationships, and the need for large multi-site clinical trials. Come and learn the benefits, obstacles, and controversies as we explore the current state and future of CER.
For more information, visit: http://esa.nih.gov/oer/training/step/step_training_20111208.htm
STEP Comparative Effectiveness Research: Choppy Waters or Smooth Sailing? (HHS Only)
-
- Advisory Committee to the Director (ACD) December 2011 Meeting (Day 2)
-
- - National Institutes of Health, Office of the Director (2011/12/14)
- - Category : Advisory Committee to the Director of the NIH
- Bi-annual meeting of the Advisory Committee to the Director. The Committee will provide advice on matters pertinent to National Institutes of Health (NIH) mission responsibilities in the conduct and support of biomedical research, medical science, and biomedical communications.
For more information, visit: http://acd.od.nih.gov/
Advisory Committee to the Director (ACD) December 2011 Meeting (Day 2)
-
- Treatment of Cancer with Recombinant Immunotoxins: from Technology Transfer to the Patient
-
- - Ira Pastan, M.D. (2011/12/14)
- - Category : Philip S. Chen
- The 6th Annual Philip S. Chen, Jr. Distinguished Lecture on Innovation and Technology Transfer
Treatment of Cancer with Recombinant Immunotoxins: from Technology Transfer to the Patient
-
- Is It Ethical to Give Presents to Patients
-
- - Philip M. Rosoff, MD, MA, Director, Clinical Ethics Program, Duke University Hospital and Professor of Pediatrics (Hematology and Oncology) and Professor of Medicine, Duke University Medical Center (2011/12/13)
- - Category : Clinical Center Grand Rounds
- Clinical Center Ethics Rounds
Is It Ethical to Give Presents to Patients
-
- Bittersweet Roles of O-GlcNAcylation in Diabetes, Alzheimer？？？s Disease and Cancer
-
- - Dr. Gerald W. Hart, Johns Hopkins University (2011/12/13)
- - Category : Wednesday Afternoon Lectures
- O-GlcNAcylation, the cycling of a N-acetylglucosamine monosaccharide on Ser(Thr) residues of nuclear and cytoplasmic proteins, serves as a nutrient/stress sensor to regulate signaling, transcription and cellular metabolism. Recent phospho- and glycomic approaches have shown that an increase in global O-GlcNAcylation affects phospho-site occupancy at nearly every actively cycling site. A chemico-enzymatic photochemical enrichment method, combined with ETD-mass spectrometry allows detection of O-GlcNAc site occupancy at a level of sensitivity comparable to that possible for phosphorylation. These analyses show that crosstalk between site-specific phosphorylation and O-GlcNAcylation is extensive. Many kinases are both modified and regulated by O-GlcNAcylation. The major sensor of cellular energy state, AMPK is O-GlcNAcylated. AMPK and O-GlcNAc transferase share many substrates and the two systems directly interact. Major signaling cascades (eg. CDK1, aurora kinase, polo kinase) that regulate cell division are strikingly affected by a small change in O-GlcNAcylation. O-GlcNAc is part of the histone code, but many of the O-GlcNAc residues are at sites interacting with DNA in the nucleosome, not in the histone tails. Multiple core ribosome proteins are modified by O-GlcNAc, which plays a role in ribosome biogenesis and assembly. O-GlcNAc cycling is strikingly elevated in most forms of cancer. Excessive O-GlcNAcylation of regulatory proteins appears to underlie glucose toxicity associated with diabetes. In the brain, reduced O-GlcNAcylation of many proteins is associated with neurodegenerative disease. Thus, O-GlcNAcylation modulates many signaling cascades and phosphate-mediated molecular switches to ？？tune？？ them to be highly responsive to nutrients and stress.
The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
For more information, visit:
The NIH Directors Wednesday Afternoon Lecture Series
Bittersweet Roles of O-GlcNAcylation in Diabetes, Alzheimer？？？s Disease and Cancer
-
- Advisory Committee to the Director (ACD) December 2011 Meeting (Day 1)
-
- - National Institutes of Health, Office of the Director (2011/12/11)
- - Category : Advisory Committee to the Director of the NIH
- Bi-annual meeting of the Advisory Committee to the Director. The Committee will provide advice on matters pertinent to National Institutes of Health (NIH) mission responsibilities in the conduct and support of biomedical research, medical science, and biomedical communications.
For more information, visit: http://acd.od.nih.gov/
Advisory Committee to the Director (ACD) December 2011 Meeting (Day 1)
-
- Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 1)
-
- - NCI, CDC, and OMAR (2011/12/10)
- - Category : Conferences
- Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. It is estimated that in 2010, approximately 32,000 American men died of prostate cancer and 218,000 were newly diagnosed with the disease. Most prostate cancers are detected by a blood test that measures prostate-specific antigen (PSA), a tumor marker. More than half of cancers detected with PSA screening are localized (confined to the prostate) and are not aggressive at diagnosis, and are unlikely to become life-threatening.
However, 90 percent of patients receive immediate treatment for prostate cancer, such as surgery or radiation therapy. In many patients, these treatments have substantial short- and long-term side effects without any clinical benefit. Appropriate management of screen-detected, early-stage, low-risk prostate cancer is an important public health issue given the number of men affected and the risk for adverse outcomes, such as diminished sexual function and loss of urinary control. Currently clinicians rely on two observational strategies as alternatives to immediate treatment of early-stage prostate cancer: watchful waiting and active surveillance.
To better understand the benefits and risks of active surveillance and other observational management strategies for PSA screening-detected, low-grade, localized prostate cancer, the National Institutes of Health has engaged in a rigorous assessment of the available scientific evidence. This process, sponsored by the National Cancer Institute, the Centers for Disease Control and Prevention, and the Office of Medical Applications of Research will culminate in a Consensus Development Conference December 5？？？7, 2011.
For more information, visit: http://consensus.nih.gov/
Role of Active Surveillance in the Management of Men With Localized Prostate Cancer (Day 1)
-
- National Cancer Advisory Board - December 2011
-
- - NCI (2011/12/10)
- - Category : National Cancer Advisory Board
- The National Cancer Advisory Board Meeting
National Cancer Advisory Board - December 2011
-
- TRACO: Nanotechnology
-
- - Jennifer Hall (2011/12/09)
- - Category : TRACO
- The Translational Research in Clinical Oncology (TRACO) course will be held on Monday afternoons from September to December at the Bethesda campus, Bldg. 50 ground floor auditorium. TRACO is designed to provide an overview of general principles of cancer biology and treatment, epidemiology, mechanisms of resistance, metastasis, use of preclinical models, and identification of novel molecular targets. Participants will have an unprecedented opportunity to learn new information, glimpse into future developments of translational research in clinical oncology, meet leaders in cancer research, and interview cancer survivors. These courses are part of a curriculum for training NCI clinical and postdoctoral fellows.
For more information, visit: http://ccr.cancer.gov/careers/courses/traco
TRACO: Nanotechnology
-
- Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy (Day 1)
-
- - NIH, USDA, NCI-DCP-DNRC-NCIFrederick-NCL, NIBIB, NCCAM, ODS (2011/12/08)
- - Category : Conferences
- The "Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy" will discuss and evaluate the state of the science and identify knowledge gaps in the use of nutrients (and bioactive food components) for disease prevention and opportunities to improve safe, targeted delivery and controlled release of these components to improve absorption, distribution, metabolism, and elimination through nanotechnologies. The workshop also aims to encourage collaborations and stimulate ideas for diet and disease prevention research.
Sessions will highlight several emerging areas of potential utility in nutrition and food science research, including ？？？Knowledge Gaps in Effective Nutrition and Disease Prevention,？？？ ？？？Applications of Nanotechnology To Enhance Nutrition for Disease Prevention,？？？ ？？？Opportunities and Challenges in the Food Sciences With Nanotechnologies,？？？ and ？？？Ethical, Legal, and Societal Implications of Nutritional Nanotechnology.？？？
For more information, visit: http://event.cabezongroup.com/meeting/2011/NNM/
Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy (Day 1)
-
- Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy (Day 2)
-
- - NIH, USDA, NCI-DCP-DNRC-NCIFrederick-NCL, NIBIB, NCCAM, ODS (2011/12/08)
- - Category : Conferences
- The "Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy" will discuss and evaluate the state of the science and identify knowledge gaps in the use of nutrients (and bioactive food components) for disease prevention and opportunities to improve safe, targeted delivery and controlled release of these components to improve absorption, distribution, metabolism, and elimination through nanotechnologies. The workshop also aims to encourage collaborations and stimulate ideas for diet and disease prevention research.
Sessions will highlight several emerging areas of potential utility in nutrition and food science research, including ？？？Knowledge Gaps in Effective Nutrition and Disease Prevention,？？？ ？？？Applications of Nanotechnology To Enhance Nutrition for Disease Prevention,？？？ ？？？Opportunities and Challenges in the Food Sciences With Nanotechnologies,？？？ and ？？？Ethical, Legal, and Societal Implications of Nutritional Nanotechnology.？？？
For more information, visit: http://event.cabezongroup.com/meeting/2011/NNM/
Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy (Day 2)